Breaking News Instant updates and real-time market news.

PBYI

Puma Biotechnology

$25.01

1.32 (5.57%)

08:10
01/11/19
01/11
08:10
01/11/19
08:10

Puma Biotechnology, Knight Therapeutics enter into license agreement for NERLYNX

Puma Biotechnology announced that it has entered into an exclusive License Agreement with Knight Therapeutics that grants Knight the exclusive right to commercialize NERLYNX in Canada. Puma Biotechnology filed a new drug submission for NERLYNX with Health Canada in July 2018 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy. Under the terms of the License Agreement, Knight will be responsible for all commercial activities and future regulatory submissions for NERLYNX in Canada. Puma will receive upfront and milestone payments up to $7.2M throughout the term of this agreement, as well as double digit royalties on net sales of NERLYNX in Canada. Neratinib was approved by the U.S. Food and Drug Administration in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX tablets.

PBYI Puma Biotechnology
$25.01

1.32 (5.57%)

12/06/18
RBCM
12/06/18
NO CHANGE
Target $26
RBCM
Sector Perform
Puma Biotechnology price target lowered to $26 from $52 at RBC Capital
RBC Capital analyst Kennen MacKay lowered his price target on Puma Biotechnology to $26 and kept his Sector Perform rating after attending the presentation on the updated KATHERINE data in high-risk adjuvant human epidermal growth factor receptor 2, or HER2, / breast cancer at the San Antonio Breast Cancer Symposium. The analyst cites increased competition for Puma's Nerlynx coming from Genentech's Kadcyla's entry into the breast cancer market with indicated benefits for high risk patients and "strong benefit in HER2+/HR+ patients" where Nerlynx was expected to generate most of its sales.
12/18/18
CANT
12/18/18
NO CHANGE
Target $55
CANT
Overweight
Puma Biotechnology price target raised to $55 from $50 at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young raised her price target for Puma Biotechnology to $55 after the company released the Phase 3 NALA study in HER2+ metastatic breast cancer patients. The analyst increased her probability of success to 75% from 25% in her base case, which adds $5 per share. Young now models an incremental $150M in 2023 for Nerlynx sales from HER2+ metastatic breast cancer sales. The general expectation from investors was that the trial would likely fail, so the stock should be up on the news, Young tells investors in a research note. She thinks the NALA readout "lifts an overhang on the Puma story" and that Puma's Q4 earnings "may now be a major catalyst for the stock."
12/18/18
RBCM
12/18/18
NO CHANGE
Target $29
RBCM
Sector Perform
Puma Biotechnology price target raised to $29 from $26 at RBC Capital
RBC Capital analyst Kennen MacKay raised his price target on Puma Biotechnology to $29 after its release of a positive phase 3 NALA trial data which "could establish Nerlynx as Standard of Care in 3L+ metastatic HER2+ breast cancer on paper". The analyst also keeps his Sector Perform rating on the shares, adding that the "commercial uptake" for the program remains a "concern" amid the changes in Standard of Care model to off-label therapies, which he says should keep the stock as a "show me" story.
01/03/19
GUGG
01/03/19
DOWNGRADE
GUGG
Neutral
Puma Biotechnology downgraded to Neutral from Buy at Guggenheim

TODAY'S FREE FLY STORIES

LPCN

Lipocine

$2.24

0.65 (40.88%)

12:17
01/17/19
01/17
12:17
01/17/19
12:17
Recommendations
Lipocine analyst commentary  »

Ladenburg reiterates Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
01/17/19
01/17
12:17
01/17/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMB

Limbach Holding

$5.00

(0.00%)

12:16
01/17/19
01/17
12:16
01/17/19
12:16
Hot Stocks
Limbach awarded contracts totaling $81.4M for hospital construction »

Limbach Holdings provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
01/17/19
01/17
12:16
01/17/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPCN

Lipocine

$2.27

0.68 (42.77%)

12:12
01/17/19
01/17
12:12
01/17/19
12:12
Periodicals
Lipocine NASH data contain plenty of 'red flags,' STAT's Feuerstein writes »

This morning's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVE

Cenovus Energy

$7.79

-0.19 (-2.38%)

12:10
01/17/19
01/17
12:10
01/17/19
12:10
Options
Second day of call buying in Cenovus Energy continues as shares slump »

Second day of call buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SQ

Square

$68.79

2.9 (4.40%)

12:04
01/17/19
01/17
12:04
01/17/19
12:04
Hot Stocks
Square launches free debit card for business, with sellers access to funds »

Square announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 03

    Mar

ALBO

Albireo Pharma

$24.54

0.08 (0.33%)

12:03
01/17/19
01/17
12:03
01/17/19
12:03
Hot Stocks
Albireo Pharma treatment of biliary atresia granted FDA orphan status »

Albireo Pharma's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPOR

Gulfport Energy

$8.67

-0.23 (-2.58%)

12:02
01/17/19
01/17
12:02
01/17/19
12:02
Hot Stocks
Gulfport Energy confirms receipt of Firefly letter »

Gulfport Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNFI

United Natural Foods

$13.09

-2.32 (-15.06%)

12:00
01/17/19
01/17
12:00
01/17/19
12:00
Hot Stocks
United Natural Foods falls -15.1% »

United Natural Foods is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESTE

Earthstone Energy

$5.28

-1.49 (-22.01%)

12:00
01/17/19
01/17
12:00
01/17/19
12:00
Hot Stocks
Earthstone Energy falls -21.9% »

Earthstone Energy is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIG

Signet Jewelers

$25.49

-7.885 (-23.63%)

12:00
01/17/19
01/17
12:00
01/17/19
12:00
Hot Stocks
Signet Jewelers falls -23.6% »

Signet Jewelers is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKX

Skechers

$27.64

2.27 (8.95%)

12:00
01/17/19
01/17
12:00
01/17/19
12:00
Hot Stocks
Skechers rises 9.2% »

Skechers is up 9.2%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSV

Carriage Services

$18.60

1.61 (9.48%)

12:00
01/17/19
01/17
12:00
01/17/19
12:00
Hot Stocks
Carriage Services rises 9.6% »

Carriage Services is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

SNH

Senior Housing

$12.82

-0.07 (-0.54%)

12:00
01/17/19
01/17
12:00
01/17/19
12:00
Options
Put buyers in Senior Housing Properties »

Put buyers in Senior…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLD

Sears

$0.00

(0.00%)

12:00
01/17/19
01/17
12:00
01/17/19
12:00
Hot Stocks
Sears confirms ESL selected as winning bidder in bankruptcy auction »

Sears Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OZM

Och-Ziff Capital

$12.51

1.27 (11.30%)

12:00
01/17/19
01/17
12:00
01/17/19
12:00
Hot Stocks
Och-Ziff Capital rises 11.1% »

Och-Ziff Capital is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$68.66

0.78 (1.15%)

, PLCE

Children's Place

$87.83

2.66 (3.12%)

11:57
01/17/19
01/17
11:57
01/17/19
11:57
Periodicals
Target revamps its baby line Cloud Island to include essential items, CNBC says »

With the demise of …

TGT

Target

$68.66

0.78 (1.15%)

PLCE

Children's Place

$87.83

2.66 (3.12%)

CRI

Carter's

$78.68

0.48 (0.61%)

GPS

Gap

$25.28

0.38 (1.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

EBS

Emergent BioSolutions

$65.86

0.79 (1.21%)

, AMPH

Amphastar

$21.90

0.1 (0.46%)

11:57
01/17/19
01/17
11:57
01/17/19
11:57
Recommendations
Emergent BioSolutions, Amphastar analyst commentary  »

Wells says naloxone news…

EBS

Emergent BioSolutions

$65.86

0.79 (1.21%)

AMPH

Amphastar

$21.90

0.1 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EBS

Emergent BioSolutions

$65.86

0.79 (1.21%)

, AMPH

Amphastar

$21.91

0.11 (0.50%)

11:55
01/17/19
01/17
11:55
01/17/19
11:55
Hot Stocks
FDA commissioner describes efforts to support development of OTC naloxone »

FDA Commissioner Scott…

EBS

Emergent BioSolutions

$65.86

0.79 (1.21%)

AMPH

Amphastar

$21.91

0.11 (0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:55
01/17/19
01/17
11:55
01/17/19
11:55
General news
Treasury Option Action: a rash of put positioning »

Treasury Option Action: a…

NFLX

Netflix

$352.83

1.68 (0.48%)

11:54
01/17/19
01/17
11:54
01/17/19
11:54
On The Fly
Fly Intel: What to watch in Netflix earnings report »

Netflix (NFLX) is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

11:45
01/17/19
01/17
11:45
01/17/19
11:45
General news
Treasury's 4- and 8-week bill auctions were solid and priced very well »

Treasury's 4- and…

WFC

Wells Fargo

$48.74

-0.19 (-0.39%)

11:40
01/17/19
01/17
11:40
01/17/19
11:40
Options
Size call butterfly spread in Wells Fargo after earnings »

Size call butterfly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Feb

  • 12

    Apr

  • 28

    May

  • 13

    Jul

  • 12

    Oct

11:35
01/17/19
01/17
11:35
01/17/19
11:35
General news
8-Week Bill Auction Total Amount data reported »

8-Week Bill Auction Total…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.